Elevated blood favipiravir levels are inversely associated with ferritin levels and induce the elevation of uric acid levels in COVID-19 treatment: A retrospective single-center study

Optimization of Analytical Procedure for In-hospital Rapid Quantification of Serum Level of Favipiravir in the Pharmacological Treatment of COVID-19

(2021) Yukiko MORIIWA et al.   ANALYTICAL SCIENCES

Population pharmacokinetics of favipiravir in patients with COVID‐19

(2021) Kei Irie et al.   CPT-Pharmacometrics & Systems Pharmacology

Remdesivir for the Treatment of Covid-19 — Preliminary Report

(2020) John H. Beigel et al.   NEW ENGLAND JOURNAL OF MEDICINE

AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

(2020) Andrey A Ivashchenko et al.   CLINICAL INFECTIOUS DISEASES

Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents

(2020) Markus Zeitlinger et al.   CLINICAL PHARMACOKINETICS

A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19

(2020) Yohei Doi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis

(2020) Petek Eylul Taneri et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial

(2020) Yan Lou et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19

(2020) Christoph D. Spinner et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis

(2020) Dhan Bahadur Shrestha et al.   Virology Journal

Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia

(2020) Faryal Khamis et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza

(2020) Yeming Wang et al.   EBioMedicine

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

(2020) Zarir F. Udwadia et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted

(2017) Thi Huyen Tram Nguyen et al.   PLoS Neglected Tropical Diseases